drugset / Trial / NCT05230290

Clinical Study of KD6001 in Advanced Solid Tumours

NCT05230290

Phase 1 Completed 13 enrolled Shanghai Kanda Biotechnology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and clinical activity of KD6001 as treatment for participants with advanced solid tumours.

Timeline

Start
2020-09-10
Primary completion
2022-07-20
Completion
2022-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject KD6001 Unknown Intravenous

Indications